the effect of chronic treatment with the luteinizing hormone-releasing hormone ( lh-rh ) agonist buserelin ( hoechst ag , frankfurt/main , west germany ) ( [ d-ser ( tbu ) 6 , des-gly-nh2 ( 10 ) ] lh-rh ethylamide ) administrered by nasal spray ( 200 or 500 micrograms , twice daily ) or subcutaneously ( 50 micrograms daily ) for periods of 1 to 8 months was studied on serum sex steroids and lh levels in 18 patients with cancer of the prostate .
C0006456
buserelin
C0023610
lh-rh